ArticleFamily medicine2026
Hepatitis C Treatment by Early-Career US Family Physicians.
Article in Family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDespite highly effective therapies for the hepatitis C virus (HCV), treatment rates remain low. Management of HCV is shifting to primary care, and family physicians are positioned to provide this care. Our objective was to determine the extent of early-career family physicians' provision of HCV treatment.
methodsWe merged 2016-2023 data from the American Board of Family Medicine National Graduate Survey, which is administered 3 years after completing residency, with state-level HCV mortality data from the Centers for Disease Control and Prevention (2017-2021). We conducted bivariate analyses to examine differences in HCV treatment by physician characteristics, practice type, and practice location. We created maps to visually explore HCV treatment and mortality by state.
resultsOverall, less than 20% of early-career family physicians reported treating HCV patients. Early-career family physicians HCV treatment rates exceeded 25% in 2016 and 2017, with rates falling to below 15% from 2018 to 2020, before rebounding to 23% in 2023. Early-career family physicians who were males, had MDs (compared to DOs), were international medical graduates, and were in nonmetropolitan areas and in medically underserved area practice types had significantly higher HCV treatment rates. State-level variation was observed, with higher early-career HCV treatment rates in states with higher HCV mortality.
conclusionsWhile HCV treatment has been simplified over the past decade, HCV treatment by early-career family physicians has declined. Despite this decline, early-career family physicians have higher rates of HCV treatment in higher-need areas and in medically underserved practice settings. Supporting family physicians through education, clinical exposure, and incentives may increase provision of HCV care to address unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.